Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

A day of celebration that Forestville Elementary School has fostered for more than four decades was held last month. The ...

This enzyme is key to DNA repair in cells, so blocking it leads to cell death. Though PARP inhibitors are already approved to treat certain cancers, they come with toxicity risks thought to be ...

PARP kicked off on Feb. 6 with an evening event organized by library media specialist Tara Gonzalez. More than 150 students visited the reading stations led by teachers and parent volunteers.

Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure in hard-to-treat cancer cells, says CEO Dr. Adrian Schomburg.